Gardel clinical trial with once daily variation
Mar 2, 2014
Dear Dr. Young, The GARDEL clinical trial (NTC reference NCT01237444) concluded that viral suppression can be achieved with a regimen of 2 active drugs (Lamivudine plus Kaletra). The trial was done with twice-daily dosage of each of these drugs. Since both drugs can also be administered once daily, would taking them that way achieve the same result? Thank you. With kind regards, Santiago.
Response from Dr. Young
Hello Santiago and thanks for posting your interesting question.
I was lucky to ask your question to Dr. Pedro Cahn, my colleague, friend, and the lead investigator for GARDEL study. He said that GARDEL used twice daily Kaletra because this dosing tends to be much better tolerated than once-daily Kaletra treatment; and in some countries, once-daily Kaletra is not approved for use.
We speculated that the twice daily has slightly better pharmacokinetic properties too. Thinking outside of the study, it would be reasonable to speculate that once someone was stable, undetectable and tolerating the twice daily regimen that a switch/simplification to once-daily could be considered.
One has to wonder if similar results could have been achieved with other better tolerated, once-daily boosted PIs. But that wasn't the study.
Hope that helps, BY
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.